Alphatec (ATEC) Secures Exclusive U.S. Rights to OsteoAdapt® Platform in Major Strategic Alignment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy ATEC?
Source: PRnewswire
- Strategic Partnership: ATEC has entered into a strategic partnership with Theradaptive, securing exclusive U.S. commercial rights to the OsteoAdapt® bone graft, which is expected to deliver long-term value through upfront and milestone payments along with a perpetual royalty structure.
- Technological Innovation: OsteoAdapt leverages AMP2™ protein technology and is currently undergoing clinical trials for spinal and dental applications, having received three FDA Breakthrough Device Designations, indicating its potential to revolutionize the bone regeneration market and render traditional grafts and synthetic alternatives obsolete.
- Funding Initiative: Theradaptive has initiated a Series B funding round to support the completion of clinical studies and rapid scaling of its technology platform, which is expected to advance the OASIS pivotal trial and provide manufacturing scale-up for future commercialization.
- Market Opportunity: The U.S. spine surgery market exceeds $10 billion annually, with the biologics segment representing a $2+ billion opportunity, and ATEC's sales force is poised to maximize market penetration, thereby generating ongoing royalty revenue for Theradaptive.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATEC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATEC
Wall Street analysts forecast ATEC stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 7.570
Low
20.00
Averages
24.33
High
28.00
Current: 7.570
Low
20.00
Averages
24.33
High
28.00
About ATEC
Alphatec Holdings, Inc., through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company. It is focused on the design, development, and advancement of technology for better surgical treatment of spine disorders. Its Organic Innovation Machine is focused on developing new approaches that integrate with its expanding InformatiX Platform to better inform surgery and safely and reproducibly achieve the goals of spine surgery. Its technologies include InformatiX, positioners, access systems, implants and fixation systems, and biologics. Its InformatiX product platform comprises EOS imaging system, EOS Insight alignment assessment and surgical planning web/mobile platform, SafeOp Neural InformatiX System and navigation-enabled robotics platform. It has developed approach-specific patient positioning systems that integrate with its other access systems, providing for a more rigid construct and enhanced reproducibility.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alphatec Holdings Under Investigation for Securities Violations
- Poor Financial Performance: Alphatec Holdings reported first-quarter 2026 results that missed consensus revenue estimates, with deliveries lower than the prior year, resulting in reduced revenue recognition and highlighting operational challenges faced by the company.
- Lowered Full-Year Outlook: The company revised its 2026 EOS revenue outlook downward, citing installation timing issues that prevented fulfillment of committed units, reflecting pressure in market competition and execution capabilities.
- Significant Stock Price Drop: On May 6, 2026, Alphatec's stock plummeted by $3.24, or 31.7%, closing at $6.99 per share, severely impacting investor confidence and potentially triggering legal claims.
- Legal Investigation Initiated: The Law Offices of Howard G. Smith announced an investigation into Alphatec on behalf of investors to pursue claims for losses incurred due to the company's possible violations of federal securities laws, indicating growing concerns over corporate governance and compliance.
See More
Alphatec Holdings Under Investigation for Securities Violations
- Underperformance in Financials: Alphatec reported total revenue of $192 million for Q1 2026, falling short of internal expectations primarily due to poor EOS sales performance, indicating pressure in market competitiveness.
- EOS Revenue Downgrade: The company revised its full-year 2026 EOS revenue outlook down from $85 million to $77 million, reflecting installation execution issues that delayed revenue recognition, potentially impacting future cash flow and investor confidence.
- Significant Stock Decline: Following the earnings report, Alphatec's stock price plummeted from $10.23 to $6.99 per share, a drop of approximately 32%, signaling heightened market concerns regarding the company's future performance and possibly diminishing investor confidence.
- Ongoing Legal Investigation: Kirby McInerney LLP is investigating potential violations of federal securities laws by Alphatec and its senior management, with no lawsuits filed yet, prompting investors to stay alert for developments to safeguard their interests.
See More
Lisanti Capital Fully Exits Alphatec Stake Amid Declining Performance
- Complete Exit: On May 6, 2026, Lisanti Capital Growth disclosed in an SEC filing that it liquidated its entire position of 372,407 shares in Alphatec, valued at approximately $5.42 million, indicating a pessimistic outlook on the company's future prospects.
- Significant Market Decline: Alphatec's market capitalization stands at $1.06 billion, with a 42.6% drop in share price over the past year, underperforming the S&P 500 by 73.9 percentage points, reflecting market skepticism regarding its growth potential.
- Revised Performance Expectations: Although Alphatec's core surgical business has seen growth in new cases and surgeons, its EOS imaging division has underperformed, leading management to lower full-year revenue guidance, highlighting the challenges the company faces.
- Investor Confidence Shaken: Lisanti Capital's exit suggests that despite strong procedural adoption, if one segment underperforms, investors may question the company's long-term growth capabilities, adversely affecting stock performance.
See More
Alphatec Faces Investigation for Possible Securities Fraud
- Investigation Launched: Ademi LLP is investigating Alphatec (NASDAQ: ATEC) for possible securities fraud due to potentially inaccurate statements regarding its financial statements, business operations, and prospects, which could lead to investor losses.
- Operational Issues Acknowledged: On May 6, 2026, Alphatec acknowledged operational issues with its EOS business, a statement that may heighten investor concerns about the company's future performance and negatively impact its stock price.
- Increased Legal Risks: The potential securities fraud allegations expose Alphatec to legal litigation risks, which could result in substantial financial liabilities in the future, affecting the company's financial stability.
- Investor Confidence Shaken: As the investigation unfolds, investor confidence in Alphatec may wane, leading shareholders to question the company's governance and transparency, thereby impacting its market reputation.
See More
Alphatec Holdings Under Investigation for Potential Investor Claims
- Financial Performance Miss: Alphatec reported total revenue of $192 million for Q1 2026, falling short of internal expectations primarily due to poor EOS sales performance, which has negatively impacted investor confidence.
- EOS Revenue Downgrade: The company revised its full-year 2026 EOS revenue outlook down from $85 million to approximately $77 million, reflecting installation execution issues and unfulfilled unit commitments, which could hinder future revenue growth.
- Stock Price Decline: Following the earnings report, Alphatec's stock price sharply declined, damaging investor interests and prompting Johnson Fistel to investigate whether the company complied with federal securities laws.
- Law Firm Involvement: Johnson Fistel, PLLP is representing investors in investigating Alphatec's executives to assess the potential for recovering investment losses under federal securities laws, highlighting a commitment to protecting investor rights.
See More
Alphatec Reports Breakeven Q1 Non-GAAP Results
- Performance Shift: Alphatec reported breakeven non-GAAP results for Q1, indicating a successful transition from previous losses, which reflects an improvement in its financial condition.
- Market Reaction: Despite not achieving profitability, the market's neutral response to the breakeven results suggests cautious optimism among investors regarding the company's future growth potential.
- Strategic Adjustments: The company may have achieved breakeven through operational optimization and cost control measures, demonstrating its adaptability in the current economic environment.
- Future Outlook: As market demand gradually recovers, Alphatec is positioned to potentially achieve profitability in upcoming quarters, further solidifying its market position in the medical device industry.
See More
Alphatec Holdings Under Investigation for Securities Violations
- Poor Financial Performance: Alphatec Holdings reported first-quarter 2026 results that missed consensus revenue estimates, with deliveries lower than the prior year, resulting in reduced revenue recognition and highlighting operational challenges faced by the company.
- Lowered Full-Year Outlook: The company revised its 2026 EOS revenue outlook downward, citing installation timing issues that prevented fulfillment of committed units, reflecting pressure in market competition and execution capabilities.
- Significant Stock Price Drop: On May 6, 2026, Alphatec's stock plummeted by $3.24, or 31.7%, closing at $6.99 per share, severely impacting investor confidence and potentially triggering legal claims.
- Legal Investigation Initiated: The Law Offices of Howard G. Smith announced an investigation into Alphatec on behalf of investors to pursue claims for losses incurred due to the company's possible violations of federal securities laws, indicating growing concerns over corporate governance and compliance.
See More
Alphatec Holdings Under Investigation for Securities Violations
- Underperformance in Financials: Alphatec reported total revenue of $192 million for Q1 2026, falling short of internal expectations primarily due to poor EOS sales performance, indicating pressure in market competitiveness.
- EOS Revenue Downgrade: The company revised its full-year 2026 EOS revenue outlook down from $85 million to $77 million, reflecting installation execution issues that delayed revenue recognition, potentially impacting future cash flow and investor confidence.
- Significant Stock Decline: Following the earnings report, Alphatec's stock price plummeted from $10.23 to $6.99 per share, a drop of approximately 32%, signaling heightened market concerns regarding the company's future performance and possibly diminishing investor confidence.
- Ongoing Legal Investigation: Kirby McInerney LLP is investigating potential violations of federal securities laws by Alphatec and its senior management, with no lawsuits filed yet, prompting investors to stay alert for developments to safeguard their interests.
See More
Lisanti Capital Fully Exits Alphatec Stake Amid Declining Performance
- Complete Exit: On May 6, 2026, Lisanti Capital Growth disclosed in an SEC filing that it liquidated its entire position of 372,407 shares in Alphatec, valued at approximately $5.42 million, indicating a pessimistic outlook on the company's future prospects.
- Significant Market Decline: Alphatec's market capitalization stands at $1.06 billion, with a 42.6% drop in share price over the past year, underperforming the S&P 500 by 73.9 percentage points, reflecting market skepticism regarding its growth potential.
- Revised Performance Expectations: Although Alphatec's core surgical business has seen growth in new cases and surgeons, its EOS imaging division has underperformed, leading management to lower full-year revenue guidance, highlighting the challenges the company faces.
- Investor Confidence Shaken: Lisanti Capital's exit suggests that despite strong procedural adoption, if one segment underperforms, investors may question the company's long-term growth capabilities, adversely affecting stock performance.
See More
Alphatec Faces Investigation for Possible Securities Fraud
- Investigation Launched: Ademi LLP is investigating Alphatec (NASDAQ: ATEC) for possible securities fraud due to potentially inaccurate statements regarding its financial statements, business operations, and prospects, which could lead to investor losses.
- Operational Issues Acknowledged: On May 6, 2026, Alphatec acknowledged operational issues with its EOS business, a statement that may heighten investor concerns about the company's future performance and negatively impact its stock price.
- Increased Legal Risks: The potential securities fraud allegations expose Alphatec to legal litigation risks, which could result in substantial financial liabilities in the future, affecting the company's financial stability.
- Investor Confidence Shaken: As the investigation unfolds, investor confidence in Alphatec may wane, leading shareholders to question the company's governance and transparency, thereby impacting its market reputation.
See More
Alphatec Holdings Under Investigation for Potential Investor Claims
- Financial Performance Miss: Alphatec reported total revenue of $192 million for Q1 2026, falling short of internal expectations primarily due to poor EOS sales performance, which has negatively impacted investor confidence.
- EOS Revenue Downgrade: The company revised its full-year 2026 EOS revenue outlook down from $85 million to approximately $77 million, reflecting installation execution issues and unfulfilled unit commitments, which could hinder future revenue growth.
- Stock Price Decline: Following the earnings report, Alphatec's stock price sharply declined, damaging investor interests and prompting Johnson Fistel to investigate whether the company complied with federal securities laws.
- Law Firm Involvement: Johnson Fistel, PLLP is representing investors in investigating Alphatec's executives to assess the potential for recovering investment losses under federal securities laws, highlighting a commitment to protecting investor rights.
See More
Alphatec Reports Breakeven Q1 Non-GAAP Results
- Performance Shift: Alphatec reported breakeven non-GAAP results for Q1, indicating a successful transition from previous losses, which reflects an improvement in its financial condition.
- Market Reaction: Despite not achieving profitability, the market's neutral response to the breakeven results suggests cautious optimism among investors regarding the company's future growth potential.
- Strategic Adjustments: The company may have achieved breakeven through operational optimization and cost control measures, demonstrating its adaptability in the current economic environment.
- Future Outlook: As market demand gradually recovers, Alphatec is positioned to potentially achieve profitability in upcoming quarters, further solidifying its market position in the medical device industry.
See More
